TelyRx Announces Year-End 2025 Financial Results

• Most Recent Release (2026-04-21): TelyRx Holdings Inc. announced audited Year-End 2025 financial results. Annual revenue reached $42.9 million, a significant increase from $9.5 million in FY 2024. Q4 2025 revenue was $14.3 million, up from $12.3 million in Q3 and $4.6 million in Q4 2024. Prescription volume surged to 177,713 in Q4 2025 compared to 53,390 in the prior year period.
• Previous Release (2026-04-07): The company commenced trading on the Toronto Stock Exchange (TSX) under ticker "TELY" following a combination with Apolo V Acquisition Corp. Management highlighted coverage of over 97% of the U.S. population and 400+ FDA-approved medications.
• Price Action Context: Trading began at $3.50 on April 7, 2026. The stock experienced a decline to a low of $3.00 between April 14 and April 17 before recovering to the initial listing price of $3.50 by April 20, one day prior to earnings release.

• Revenue Growth Validation: The tripling of annual revenue ($9.5M to $42.9M) is a material positive development that validates the post-SPAC business model. It suggests successful execution in scaling operations and customer acquisition within the digital pharmacy sector.
• Volume Acceleration: Prescription fills increased by approximately 230% year-over-year (Q4 2025 vs Q4 2024), indicating strong demand elasticity and potential network effects.
• Critical Gap - Profitability: While top-line growth is impressive, the news release does not disclose net income, EBITDA, or cash flow from operations. In a risk-averse analysis, high revenue growth without confirmed profitability in a capital-intensive sector (healthcare/pharmacy) presents execution risk. The market may price this as "growth at all costs" until margins are proven.
• Market Reaction: The stock recovered to its listing price ($3.50) immediately before the earnings announcement, suggesting potential insider accumulation or market anticipation of strong results. However, without profit data, the sustainability of this valuation remains unproven.

• Business Model: Vertically integrated digital pharmacy platform combining telehealth services with prescription fulfillment.
• Flagship Project: Nationwide access to 400+ FDA-approved medications via independent physicians and retail pharmacies in Florida and Texas, serving 97% of the U.S. population.
• Development Stage: Post-SPAC merger (Apolo V Acquisition Corp), transitioning from private/SPAC structure to public TSX listing with proven revenue scaling.